Concurrent Chemoradiotherapy Containing Paclitaxel and Cisplatin With/Without Tarceva in Locally Advanced Esophageal Carcinoma: a Randomized Phase III Multi-center Trial.

Trial Profile

Concurrent Chemoradiotherapy Containing Paclitaxel and Cisplatin With/Without Tarceva in Locally Advanced Esophageal Carcinoma: a Randomized Phase III Multi-center Trial.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin; Paclitaxel
  • Indications Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Two year results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 27 Nov 2013 Planned end date changed from 1 Mar 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 27 Nov 2013 Planned number of patients changed from 325 to 512 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top